149 related articles for article (PubMed ID: 31322247)
21. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
22. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
[TBL] [Abstract][Full Text] [Related]
23. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
[No Abstract] [Full Text] [Related]
25. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
27. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
28. Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
DiSilvestro PA; Fisher M; Pearl ML; Buhl A; Chalas E; Valea FA
Gynecol Obstet Invest; 2007; 63(1):1-6. PubMed ID: 16809933
[TBL] [Abstract][Full Text] [Related]
29. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.
Li W; Wan L; Zhai LY; Wang J
Int J Mol Sci; 2014 Oct; 15(10):19265-80. PubMed ID: 25342321
[TBL] [Abstract][Full Text] [Related]
30. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Kim TJ; Ravoori M; Landen CN; Kamat AA; Han LY; Lu C; Lin YG; Merritt WM; Jennings N; Spannuth WA; Langley R; Gershenson DM; Coleman RL; Kundra V; Sood AK
Cancer Res; 2007 Oct; 67(19):9337-45. PubMed ID: 17909042
[TBL] [Abstract][Full Text] [Related]
31. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice.
Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N
Anticancer Res; 2003; 23(3B):2405-11. PubMed ID: 12894521
[TBL] [Abstract][Full Text] [Related]
33. Recurrent ovarian undifferentiated carcinoma resembling hepatoid morphology treated with pegylated liposomal doxorubicin and bevacizumab.
Ishiguro T; Kashima K; Yachida N; Motoyama T; Enomoto T
J Obstet Gynaecol Res; 2017 May; 43(5):957-961. PubMed ID: 28422375
[TBL] [Abstract][Full Text] [Related]
34. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
[TBL] [Abstract][Full Text] [Related]
35. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
36. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
37. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
38. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.
Ghosh S; Maity P
J Environ Pathol Toxicol Oncol; 2010; 29(1):17-30. PubMed ID: 20528744
[TBL] [Abstract][Full Text] [Related]
39. Investigation of combination therapy modes of bevacizumab and paclitaxel for NSCLC in vivo.
Wang J; Shen H; Jiang Q; Shu Y
Pak J Pharm Sci; 2016 Mar; 29(2 Suppl):695-9. PubMed ID: 27113309
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers.
Long Q; Xiel Y; Huang Y; Wu Q; Zhang H; Xiong S; Liu Y; Chen L; Wei Y; Zhao X; Gong C
J Biomed Nanotechnol; 2013 Jun; 9(6):965-75. PubMed ID: 23858960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
